Investigating how specific proteins can be targeted for new drug development
Profiling the specificity of SPI1 and SPIB activity for drug discovery
This study is looking at two proteins that help make blood cells and are connected to some rare diseases, with the goal of finding new ways to create medicines that could help people with conditions like leukemia and autoimmune diseases.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11032110 on NIH RePORTER |
What this research studies
This research focuses on understanding the roles of two important proteins, SPI1 and SPIB, which are involved in blood cell formation and are linked to various rare diseases. By profiling how these proteins function, the research aims to identify new ways to develop drugs that can effectively target them. The approach includes using small molecules to modulate the activity of these proteins, potentially leading to innovative treatments for conditions like leukemias and autoimmune diseases. Patients may benefit from new therapeutic options that arise from this targeted drug discovery process.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with rare hematopoietic diseases such as leukemias, lymphomas, or autoimmune disorders.
Not a fit: Patients with common, non-hematopoietic conditions or those not affected by rare diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new drugs that specifically target rare diseases related to blood cell formation.
How similar studies have performed: Other research has shown promise in targeting transcription factors for drug discovery, suggesting that this approach could yield significant advancements.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Poon, Gregory Man Kai — Georgia State University
- Study coordinator: Poon, Gregory Man Kai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.